Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
Rhea-AI Summary
Calidi Biotherapeutics (NYSE American: CLDI) reported positive pre-IND feedback from the US FDA for its oncolytic virus candidate CLD-401, providing alignment on IND-enabling preclinical plans and first-in-human trial design.
According to Calidi, IND submission is targeted by end of 2026, with Phase 1 initiation in early 2027 and potential parallel regulatory filing in Australia.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- FDA pre-IND alignment on CLD-401 CMC and non-clinical programs
- FDA feedback on overall design of first-in-human CLD-401 study
- IND submission for CLD-401 targeted by end of 2026
- First-in-human CLD-401 Phase 1 trial targeted for early 2027
- Parallel regulatory filing for CLD-401 in Australia under exploration
Negative
- None.
News Market Reaction – CLDI
On the day this news was published, CLDI declined 1.91%, reflecting a mild negative market reaction. Argus tracked a peak move of +7.8% during that session. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $61K from the company's valuation, bringing the market cap to $3.13M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Investor webinar | Positive | -0.6% | Announcement of investor webinar reviewing RedTail platform and CLD-401 plans. |
| May 26 | ASCO abstracts | Positive | +0.8% | ASCO online abstract acceptances featuring RedTail platform and CLD-401/CLD-501 data. |
| May 22 | Going-concern note | Negative | +0.8% | Disclosure of going-concern paragraph in 2025 audit under NYSE American rules. |
| May 14 | Q1 2026 earnings | Negative | -2.3% | Q1 2026 loss, limited cash, and updates on CLD-401 and RedTail platform. |
| May 13 | Conference presentation | Positive | +8.1% | ASGCT talk highlighting RedTail platform and new data for CLD-401 and CLD-501. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows stronger positive reactions to scientific/platform visibility (e.g., ASGCT presentation) and mixed reactions around corporate or financing-related disclosures.
Over the past month, Calidi has repeatedly highlighted its RedTail virotherapy platform and lead candidate CLD-401. A featured ASGCT conference talk on May 13 saw the stock rise 8.11%, while an ASCO abstract acceptance on May 26 coincided with a modest 0.8% gain. In contrast, the Q1 2026 earnings release on May 14 and a required NYSE American going‑concern disclosure produced small, mixed moves. Today’s FDA pre‑IND feedback continues the sequence of CLD‑401 and RedTail‑focused milestones.
Regulatory & Risk Context
Key Terms
pre-ind regulatory
u.s. food and drug administration (fda) regulatory
phase 1 medical
oncolytic virus medical
il-15 superagonist medical
cmc technical
first-in-human medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi continues to explore regulatory filing for CLD-401 in Australia in parallel
SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it has received pre-IND regulatory feedback from the U.S. Food and Drug Administration (FDA) providing alignment and clarity on Calidi’s IND-enabling preclinical plans and clinical strategy for CLD-401 prior to advancing the drug candidate into Phase 1 clinical studies.
“We thank the FDA for its regulatory feedback, and we believe we are in agreement with the agency on our overall IND strategy for CLD-401,” said Calidi Biotherapeutics Chief Executive Officer Eric Poma, Ph.D. “We look forward to our regulatory submission for CLD-401, a potentially ground-breaking oncolytic virus with in situ delivery of an IL-15 superagonist, which we are targeting by year-end. This positions us to initiate our first-in-human clinical trial in early 2027.”
In the pre-IND meeting, the FDA and Calidi agreed on key aspects of the CMC and non-clinical programs as well as feedback on the overall design for the proposed first-in-human clinical study. This pre-IND (Type B) interaction builds on the engagement and alignment achieved through early scientific advice as part of a Type D interaction with the FDA.
Calidi is committed to rapidly advancing CLD-401 into the clinic, believing that early Phase I data for CLD-401 will validate the Company’s proprietary RedTail platform. The Company continues to expand the functionality of the RedTail platform while actively pursuing strategic partnerships to accelerate clinical development and broaden its impact.
About Calidi
Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.
CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.
Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 27, 2026, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
For Investors:
For Media:
